Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains the leading cause of death globally and a major contributor to rising healthcare expenses for employers. According to the American Heart Association, heart disease costs the United States over $200 billion annually in healthcare services, medications, and lost productivity. By leveraging artificial intelligence to detect risk earlier, Cardio Diagnostics aims to provide a proactive approach that could shift the paradigm from reactive treatment to preventive care.
The company's core technology is an AI-driven Integrated Genetic-Epigenetic Engine that analyzes genetic and epigenetic markers to assess an individual's risk for coronary heart disease. The Epi+Gen CHD test is a clinically validated blood test that combines genetic and epigenetic biomarkers to predict a person's risk of developing coronary heart disease within three years. PrecisionCHD offers a more comprehensive assessment, incorporating additional clinical and lifestyle factors. The HeartRisk population insights platform aggregates de-identified data to provide employers and plan sponsors with actionable analytics on their covered population's cardiovascular risk profile.
These tools are particularly relevant for benefits decision-makers who are increasingly focused on value-based care and managing chronic disease. By identifying high-risk individuals before a cardiac event occurs, employers can implement targeted wellness programs, adjust plan designs, and potentially reduce costly emergency interventions. The implications for the industry are significant: if adopted widely, AI-powered risk assessments could lower insurance premiums, reduce absenteeism, and improve overall employee health outcomes.
Cardio Diagnostics will be present at four conferences in June: the Benefits Forum & Expo, the Self-Insurance Institute of America (SIIA) National Conference, the International Foundation of Employee Benefit Plans (IFEBP) Annual Conference, and the WorldatWork Total Rewards Conference. These venues provide direct access to the key stakeholders responsible for managing healthcare benefits for millions of workers.
The company's participation underscores a growing trend in the benefits industry: using advanced analytics and AI to personalize healthcare and control costs. As employers grapple with rising medical inflation, solutions that offer precise risk stratification and early intervention are becoming increasingly attractive. Cardio Diagnostics' approach aligns with broader shifts toward precision medicine and data-driven population health management.
For more information on Cardio Diagnostics and its technologies, visit the company’s newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu.
